
Oscar Health (OSCR) Stock Forecast & Price Target
Oscar Health (OSCR) Analyst Ratings
Bulls say
Oscar Health Inc. reported a significant year-over-year revenue increase of 29.0% in 2Q25, reaching $2.86 billion, driven by strong retention rates and new member additions. The company's medical loss ratio (MLR) of 91.1% exceeded consensus estimates, indicating improved cost management and enhanced operational efficiency despite market-wide challenges. Additionally, management anticipates increased utilization in 4Q25, which may positively impact future growth prospects.
Bears say
Oscar Health Inc. reported a 2Q25 operating income of ($230.5 million) and an adjusted EBITDA of ($199.4 million), both of which fell short of consensus expectations, indicating ongoing financial struggles. Additionally, the company's SG&A ratio improved to 18.7%, a decline of 90 basis points year-over-year, yet this is unlikely to sufficiently offset the significant operating losses. Furthermore, management anticipates a modest decline in individual membership by year-end, raising concerns about future revenue growth and overall market positioning.
This aggregate rating is based on analysts' research of Oscar Health and is not a guaranteed prediction by Public.com or investment advice.
Oscar Health (OSCR) Analyst Forecast & Price Prediction
Start investing in Oscar Health (OSCR)
Order type
Buy in
Order amount
Est. shares
0 shares